

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, November 28, 2001

Immunex Breaks New Ground in Biotech Manufacturing with Start of BioNext Project^a in Rhode Island

Large-scale manufacturing facility next step in strategy to Increase long-term supply of ENBREL[®] (etanercept)

West Greenwich, RI - Today, Immunex Corporation [Nasdaq: IMNX] breaks ground for the BioNext Project[™], a new manufacturing plant in West Greenwich, Rhode Island. It will be dedicated to the production of ENBREL[®] (etanercept), and ultimately new products currently in development. This new facility will expand supply capacity for ENBREL, which is among the top five pharmaceutical products ever in terms of sales within the first two years of launch.

More than 300 employees and community leaders are taking part in the celebration. Speakers include Rhode Island Governor Lincoln Almond; Ed Fritzky, Immunex chairman, CEO and president; Peggy Phillips, Immunex executive vice president and chief operating officer; and West Greenwich Town Council President Thaylen Waltonen.

"Over the past six years, we've made it a priority to diversify our economy. We identified biotechnology as one of our state's growth industries," said Rhode Island Governor Lincoln Almond. "We've put incentives in place to ensure that Rhode Island is fertile ground for high-tech, cutting edge business to locate. When a company like Immunex chooses to establish roots and branch out in Rhode Island, that's proof positive that we're achieving our goal."

Once the facility is completed, the site will be one of the most advanced cell culture manufacturing centers in the world and employ up to 700 workers. The BioNext Project illustrates the rapid evolution of the biotechnology industry and the extraordinary investment companies must make in order to meet surging demand for breakthrough health care products.

"Manufacturing is a key goal given the success of our marketed products and our need for manufacturing pipeline products in the future," said Peggy Phillips. "The BioNext Project is a key element of our strategic plan to satisfy growing demand in existing and emerging markets."

The new facility, an investment of approximately \$500 million, will be built alongside an existing manufacturing plant scheduled to be acquired by Immunex on or about January 1, 2002. The existing plant's owner, Greenwich Holdings Inc., a division of American Home Products Corporation [NYSE: AHP], has been working with Immunex to retrofit the facility to produce ENBREL. In total, Immunex will have invested around \$1 billion in manufacturing in Rhode Island.

"The BioNext Project demonstrates our commitment to continuous process improvements and capital investments that increase yields and production capacity - these are the cornerstones of successful biotechnology manufacturing operations," said Efi Cohen Arazi, senior vice president of supply operations at Immunex.

When the new facility comes online, following the US Food and Drug Administration (FDA) approval expected to occur in 2005, it will likely be the fourth plant to produce ENBREL. American Home Products is also building a facility in Grange Castle, Ireland at which it intends to manufacture the drug. ENBREL is currently produced by a contract manufacturer in Germany.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

BioNext Project™ Plans

- These new facilities will be a total of 500,000 gross square feet and will include a production building, warehouse, central utility plant, and a quality laboratory.
- Estimated cost: approximately \$500 million.
- When completed, Immunex will employ up to 350 biotechnology workers at this facility, bringing total employment at the new biotech manufacturing center to up to 700.
- The BioNext Project will support 20,000 liter bioreactors -- the largest bioreactors ever used in commercial cell culture product manufacturing. (Currently, 95 percent of the biotech industry uses 100-2,000 liter bioreactors for commercial manufacturing.)
- The plant will be designed to use a new generation process technology developed by the Immunex process science group for ENBREL and other products.
- FDA approval is estimated in 2005. (FDA approval is never guaranteed; and Immunex cannot assure that any of its estimated dates relating to the Rhode Island facility will prove accurate.)

The BioNext Project design and construction teams include the following firms:

- Edward Rouse Architects, Providence, RI Architects
- Kvaerner/Kinetics, Bridgewater, NJ Engineer Architects
- Turner Construction, Boston, MA Construction Manager

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.